ストックスクリーナーアプリを入手
0.0981
1.98%
-0.0029
前日終値:
$0.101
開ける：
$0.0904
24時間の取引高:
9.71M
Relative Volume:
0.41
時価総額：
$8.55M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-5.53%
1か月 パフォーマンス:
-44.07%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.0904
$0.1094
1週間の範囲:
$0.0805
$0.1094
52週間の値動き範囲:
$0.0651
$2.22
Profusa Inc Stock (PFSA) Company Profile
PFSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.0989 | 8.73M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
127.09 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.88 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.81 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.86 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc (PFSA) 最新ニュース
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Profusa (NASDAQ: PFSA) outlines reverse split plan to address Nasdaq listing rules - Stock Titan
Profusa, Inc.Common Stock (NQ: PFSA - FinancialContent
Profusa restructures senior secured convertible notes - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Profusa expands European footprint with French distributor partnership By Investing.com - Investing.com Nigeria
Profusa expands European footprint with French distributor partnership - Investing.com India
Profusa Bolsters European Commercial Network with New French Distributor, MedSell - The Manila Times
Profusa Bolsters European Commercial Network With New French Distributor, MedSell - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring - ts2.tech
Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Profusa (PFSA) Stock Analysis Report | Financials & Insights - Benzinga
Profusa Stock Soars—To 12 Cents—On Debt Restructuring - Sahm
Profusa (PFSA) Stock: Announces Key Changes to Senior Secured Convertible Notes for Stronger Financial Health - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Trading Activity: Profusa Leads High-Volume Movers on December 30, 2025News and Statistics - IndexBox
Profusa amends securities purchase agreement to allow for $5 million note sale - Investing.com Nigeria
Here’s Why Profusa Stock (PFSA) Rocketed Today - TipRanks
US Stocks Lower; Home Price Growth Eases in October - Sahm
Profusa Restructures Senior Secured Convertible Notes; Shares Jump Pre-Bell - marketscreener.com
Profusa restructures convertible note to reduce dilution, increase flexibility - Investing.com
Profusa restructures convertible note to reduce dilution, increase flexibility By Investing.com - Investing.com South Africa
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 - The Manila Times
Profusa Signs Amendment No. 3 to Securities Purchase Agreement With Ascent Partners Fund - TradingView — Track All Markets
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
PFSA SEC FilingsProfusa Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Profusa amends equity deal and convertible note terms - MSN
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa amends securities agreements with Ascent Partners Fund - Investing.com India
Profusa Amends Equity Deal and Convertible Note Terms - TipRanks
Profusa amends securities agreements with Ascent Partners Fund By Investing.com - Investing.com UK
Profusa Updates Multiple Financing Agreements With Ascent Partners Fund - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Profusa (NASDAQ:PFSA) versus ReShape Lifesciences (OTCMKTS:RSLSD) Financial Contrast - Defense World
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Nigeria
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study - Investing.com
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
How does Profusa Inc (PFSA) change from a tortoise to a hare? - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - marketscreener.com
Profusa Inc (PFSA) 財務データ
Profusa Inc (PFSA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.20%
0.44%
大文字化:
|
ボリューム (24 時間):